#SOHO24 De Botton: in real world, median OS with Aza/Ven (10-12mos) in newly diagnosed AML shorter than seen on VIALE-A (14.7mos).

#SOHO24 De Botton: When cytopenias prolonged can extend cycle length to q5wks+ or reduce Ven duration without apparent detriment.

#SOHO24 De Botton: French group studies Aza/Ven 7+7 on basis that periods of Ven monotherapy may not be effective. ORR w 7+7 same as c/w MDACC standard of care nominally following VIALE-A.

#SOHO24 De Botton: Time to response longer w 7+7. OS the same w 7+7 as SOC Aza/Ven across ELN risk groups. Neither very effective in TP53m.

#SOHO24 De Botton: IDH mutated AML may benefit from longer Ven exposure.

#SOHO24 Craddock: AlloHCT reduces HR for relapse ~65% across all risk groups. CIBMTR data show acceptable outcomes and increasing use of alloHCT in those >70yo

#SOHO24 Craddock: AlloHCT assoc w improved OS in >60yo with AML. “The question show not be which pts should go to HCT but which pts should NOT.” PTCy further improving GRFS outcomes in older pts. (UK addressing ATG vs PTCy question which wasn’t addressed by BMTCTN 1703)

#SOHO24 Craddock: AlloHCT improves outcomes in AML whether CR achieved with intensive chemo or HMA/Ven

#SOHO24 Craddock: evidence supports use of sorafenib or gilteritinib (in MRD+) maintenance for FLT3m AML post -HCT. Ongoing studies are addressing role for post-HCT maintenance with oral Aza (UK) or Aza/Ven (VIALE-T)

#SOHO24 Craddock: AlloHCT should always be a consideration in fit AML pts regardless of age.

#SOHO24 Subklewe: an optimal target Ag for immunotherapy for AML remains wanting. CD33, CD123, and CLL1 are most clinically developed.

#SOHO24 Subklewe: still much to learn even with Gemtuzumab. GO x 2 during induction > GO x 1.

#SOHO24 Subklewe: Pivekimab and tagraxofusp targeting CD123 under study in combo with Aza/Ven, but sabatolimab and magrolimab both failed to improve outcomes with Aza/Ven.

#SOHO24 Subklewe: other CD47-SIRPa axis targeting drugs in development. Will they suffer the same fate as magro? 😬

#SOHO24 Subklewe: CRS has been a problem for BiSpAbs in AML requiring step up dosing in trials. A viable drug yet to emerge.

#SOHO24 Subklewe: using BispAb in lower disease burden (ie, MRD) may be best approach. NK cell therapies also be tested in MRD setting.

#SOHO24 Subklewe: CAR-T and CAR-NK therapies under development for AML.

#SOHO24 Subklewe: CD45 edited CAR-T could, in theory, be a pan-heme malignancy immunotherapy.

#SOHO24 Subklewe: beautiful model for development of immunotherapy in AML as definitive therapy or bridge to alloHCT. (Stellar talk!! Very hard to keep up with so much data presented…)

#SOHO24 Jayakumar (PGY2 at the podium 👏🏻): a nationwide analysis of aspirin effects in leukemia patients. Looked at >1.6M leukemia hospitalizations, 11.2% on ASA. ASA assoc w lower risks or VTE and, interestingly, bleeding and septic shock and shorter length of stay.